GD3, an overexpressed tumor-derived ganglioside, mediates the apoptosis of activated but not resting T cells.
about
Dysregulated Expression of Glycolipids in Tumor Cells: From Negative Modulator of Anti-tumor Immunity to Promising Targets for Developing Therapeutic AgentsCurcumin and tumor immune-editing: resurrecting the immune systemLysosomal storage diseases and the heat shock response: convergences and therapeutic opportunitiesGD3 synthase overexpression sensitizes hepatocarcinoma cells to hypoxia and reduces tumor growth by suppressing the cSrc/NF-kappaB survival pathway.Tumor-shed PGE(2) impairs IL2Rgammac-signaling to inhibit CD4 T cell survival: regulation by theaflavins.Re-configuration of sphingolipid metabolism by oncogenic transformation.Accumulation of long-chain glycosphingolipids during aging is prevented by caloric restriction.Curcumin reverses T cell-mediated adaptive immune dysfunctions in tumor-bearing hostsCalcarea carbonica induces apoptosis in cancer cells in p53-dependent manner via an immuno-modulatory circuit.CD1d expression in renal cell carcinoma is associated with higher relapse rates, poorer cancer-specific and overall survival.Curcumin enhances the efficacy of chemotherapy by tailoring p65NFκB-p300 cross-talk in favor of p53-p300 in breast cancer.GBM Derived Gangliosides Induce T Cell Apoptosis through Activation of the Caspase Cascade Involving Both the Extrinsic and the Intrinsic Pathway.Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells.Programmed death-1 controls T cell survival by regulating oxidative metabolism.Nifetepimine, a dihydropyrimidone, ensures CD4+ T cell survival in a tumor microenvironment by maneuvering sarco(endo)plasmic reticulum Ca2+ ATPase (SERCA).Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis.p53 and regulation of bioactive sphingolipids.Targeting human inducible regulatory T cells (Tr1) in patients with cancer: blocking of adenosine-prostaglandin E₂ cooperation.The role of the adenosinergic pathway in immunosuppression mediated by human regulatory T cells (Treg).Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy.What are regulatory T cells (Treg) regulating in cancer and why?TALEN mediated targeted editing of GM2/GD2-synthase gene modulates anchorage independent growth by reducing anoikis resistance in mouse tumor cells.Targeting the GD3 acetylation pathway selectively induces apoptosis in glioblastoma.Expression of ganglioside GD2, reprogram the lipid metabolism and EMT phenotype in bladder cancer.
P2860
Q26771367-4D05B219-D855-429B-AD89-9752ACFC0383Q26783491-2A17AAE5-A110-44C6-91A3-9B46DED38FE9Q27004531-CAC7426E-7DEE-4285-B096-57D2E6E8153FQ30944567-72A77754-F705-45F5-8E78-3DC075AAC83EQ33509284-A1806C8F-90F2-4323-990B-CA68ED28BAD4Q33649823-DFCC9E23-5E72-4E17-872C-7C7EF1D25D9BQ33936670-37098D67-0EC4-43AD-8099-9BEABAB62910Q34105756-76446215-FDC6-4CDD-9CE1-036722717A6CQ34992781-357C7ECD-3AA2-4D48-9B5A-C4947F35A078Q35136030-64AB4E57-45A3-4063-80A2-5E280290E92FQ35604870-DAC07401-A0B8-4201-8425-AE8110BEED2EQ35726496-FBBCF4C3-F01B-4DE5-8B15-2C1FCE40EB68Q35799094-FBEA4D3A-AA7C-4C2F-B0CB-24A2DAF7945CQ36036001-2D52822D-45D1-4D89-9CF7-F8219E548740Q36294691-82F6C095-57A4-42A1-9D7A-6B647E8E5084Q36665174-CF639FA9-DB6B-4FA2-A10D-6E5B5B7CCF6BQ37805092-F4F2E592-56E5-4A74-876A-68C5AB5072BDQ37894107-3861B6B4-A0AE-49E0-842F-6C33E69A3665Q37956691-425E89CC-F9CF-4D62-AEB3-17864AB47197Q37974938-03C98AAE-BC9E-4B38-ABA4-F74E5EEED1ABQ37998754-AAA59429-1D24-496B-B712-6E0B9FB522C5Q38900943-BBD412A1-87B3-4A3C-8D5F-AA5EB66DED13Q42870698-16FD752C-1E97-4E1C-BEBC-13A5FFE9E718Q47170529-DFC09883-CBAB-4E30-B7B6-B13EA4556A5F
P2860
GD3, an overexpressed tumor-derived ganglioside, mediates the apoptosis of activated but not resting T cells.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
GD3, an overexpressed tumor-de ...... vated but not resting T cells.
@en
type
label
GD3, an overexpressed tumor-de ...... vated but not resting T cells.
@en
prefLabel
GD3, an overexpressed tumor-de ...... vated but not resting T cells.
@en
P2093
P2860
P1433
P1476
GD3, an overexpressed tumor-de ...... vated but not resting T cells.
@en
P2093
Brian I Rini
Charles S Tannenbaum
Christina Moon
Cynthia M Hilston
Gaurisankar Sa
James H Finke
Patricia A Rayman
P2860
P304
P356
10.1158/0008-5472.CAN-08-3776
P407
P577
2009-03-10T00:00:00Z